Catalyst Wire Dossier Catalyst Wire Dossier

Ramucirumab

ramucirumab · Eli Lilly and Company
Drug timelines are a Plus or Pro feature.

79 regulatory and trial events tracked for Ramucirumab, covering 2014-06-17 to 2026-08-17. Get the full timeline:

Most recent: Clinical Trial Results: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]

See pricing